Trypanosoma cruzi Adjuvants Potentiate T Cell-Mediated Immunity Induced by a NY-ESO-1 Based Antitumor Vaccine
Contribuinte(s) |
UNIVERSIDADE DE SÃO PAULO |
---|---|
Data(s) |
05/11/2013
05/11/2013
2012
|
Resumo |
Immunological adjuvants that induce T cell-mediate immunity (TCMI) with the least side effects are needed for the development of human vaccines. Glycoinositolphospholipids (GIPL) and CpGs oligodeoxynucleotides (CpG ODNs) derived from the protozoa parasite Trypanosoma cruzi induce potent pro-inflammatory reaction through activation of Toll-Like Receptor (TLR) 4 and TLR9, respectively. Here, using mouse models, we tested the T. cruzi derived TLR agonists as immunological adjuvants in an antitumor vaccine. For comparison, we used well-established TLR agonists, such as the bacterial derived monophosphoryl lipid A (MPL), lipopeptide (Pam3Cys), and CpG ODN. All tested TLR agonists were comparable to induce antibody responses, whereas significant differences were noticed in their ability to elicit CD4(+) T and CD8(+) T cell responses. In particular, both GIPLs (GTH, and GY) and CpG ODNs (B344, B297 and B128) derived from T. cruzi elicited interferon-gamma (IFN-gamma) production by CD4(+) T cells. On the other hand, the parasite derived CpG ODNs, but not GIPLs, elicited a potent IFN-gamma response by CD8(+) T lymphocytes. The side effects were also evaluated by local pain (hypernociception). The intensity of hypernociception induced by vaccination was alleviated by administration of an analgesic drug without affecting protective immunity. Finally, the level of protective immunity against the NY-ESO-1 expressing melanoma was associated with the magnitude of both CD4+ T and CD8+ T cell responses elicited by a specific immunological adjuvant. Atlantic Philanthropies/Ludwig Institute for Cancer Research (LICR) - Clinical Discovery Program Atlantic Philanthropies/Ludwig Institute for Cancer Research (LICR) Clinical Discovery Program Conselho Nacional de Desenvolvimento Cientifico e Tecnologico, Brazil (CNPq) - Instituto Nacional de Ciencia e Tecnologia de Vacinas Conselho Nacional de Desenvolvimento Cientifico e Tecnologico, Brazil (CNPq) Instituto Nacional de Ciencia e Tecnologia de Vacinas Fundacao de Amparo a Pesquisa do Estado de Minas Gerais (FAPEMIG), Brazil Fundacao de Amparo a Pesquisa do Estado de Minas Gerais, Brazil (FAPEMIG |
Identificador |
PLOS ONE, SAN FRANCISCO, v. 7, n. 5, supl. 1, Part 2, pp. 110-115, MAY 2, 2012 1932-6203 http://www.producao.usp.br/handle/BDPI/41079 10.1371/journal.pone.0036245 |
Idioma(s) |
eng |
Publicador |
PUBLIC LIBRARY SCIENCE SAN FRANCISCO |
Relação |
PLOS ONE |
Direitos |
openAccess Copyright PUBLIC LIBRARY SCIENCE |
Palavras-Chave | #PATTERN-RECOGNITION RECEPTORS #REDUCING INJECTION PAIN #TOLL-LIKE RECEPTORS #HOST-RESISTANCE #INNATE IMMUNITY #PROINFLAMMATORY CYTOKINES #ADAPTIVE IMMUNITY #INTERFERON-GAMMA #DENDRITIC CELLS #TLR9 AGONISTS #MULTIDISCIPLINARY SCIENCES |
Tipo |
article original article publishedVersion |